Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 499

5.
7.

Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.

Kaplan SA, He W, Koltun WD, Cummings J, Schneider T, Fakhoury A.

Eur Urol. 2013 Jan;63(1):158-65. doi: 10.1016/j.eururo.2012.07.003.

PMID:
22831853
8.

Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.

Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.

BJU Int. 2008 Nov;102(9):1133-9. doi: 10.1111/j.1464-410X.2008.07761.x.

9.

The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality.

Gorgel SN, Sefik E, Kose O, Olgunelma V, Sahin E.

Int Braz J Urol. 2013 Sep-Oct;39(5):657-62. doi: doi: 10.1590/S1677-5538.IBJU.2013.05.07.

10.

Clinical significance of prostatic-urethral angulation on the treatment outcome of patients with symptomatic benign prostatic hyperplasia treated with tamsulosin hydrochloride.

El-Tatawy H, Gameel T, El-enen MA, Hagras A, Mousa A, El-Bahnasy AH, Raheem AA, Abu-dewan K.

Arch Ital Urol Androl. 2015 Sep 30;87(3):238-42. doi: 10.4081/aiua.2015.3.238.

11.

The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS.

Salah Azab S, Elsheikh MG.

Aging Male. 2015 Jun;18(2):89-92. doi: 10.3109/13685538.2014.967672.

PMID:
25295872
12.

Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.

Drake MJ, Chapple C, Sokol R, Oelke M, Traudtner K, Klaver M, Drogendijk T, Van Kerrebroeck P; NEPTUNE Study Group..

Eur Urol. 2015 Feb;67(2):262-70. doi: 10.1016/j.eururo.2014.07.013.

PMID:
25070148
13.

Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia.

Milicevic S, Bijelic R.

Med Arch. 2012;66(3):173-6.

PMID:
22822617
14.
15.

Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.

Yoshida M, Sugiyama Y, Masunaga K, Maeda Y, Satoji Y, Nagata T, Inadome A.

Drugs Today (Barc). 2007 Jun;43 Suppl B:1-7.

PMID:
17612712
17.

Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.

Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernández Fernández E; European Silodosin Study Group..

Eur Urol. 2011 Mar;59(3):342-52. doi: 10.1016/j.eururo.2010.10.046.

PMID:
21109344
18.

Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial.

Pande S, Hazra A, Kundu AK.

Indian J Pharmacol. 2014 Nov-Dec;46(6):601-7. doi: 10.4103/0253-7613.144912.

19.

The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.

Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F; CombAT Study Group..

Eur Urol. 2009 Feb;55(2):461-71. doi: 10.1016/j.eururo.2008.10.037.

PMID:
19013011
20.

Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.

Tsumura H, Satoh T, Ishiyama H, Tabata K, Kotani S, Minamida S, Kimura M, Fujita T, Matsumoto K, Kitano M, Hayakawa K, Baba S.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e385-92. doi: 10.1016/j.ijrobp.2011.04.026.

PMID:
21664068
Items per page

Supplemental Content

Support Center